Strategic cooperation has been formed between Camfil and Sinopharm, China to uplift the air filtration standards in the biopharma industry
Camfil, a specialist in air filtration equipment and clean air solutions, and Sinopharm GEPTECK, have announced the joint release of digital high-efficiency air supply units.
Sinopharm is the largest pharmaceutical and healthcare group under the State-Owned Assets Supervision and Administration Commission of the State Council (SASAC) in China, with the core business of pharmaceutical distribution, scientific research, and manufacture of medical and biotech products.
The initiative will target the application limitations of traditional air supply units and will set new milestones in the clean air-conditioning system in the biomedical industry.
Over the past few years, Sinopharm GEPTECK has set up an R&D-oriented development path and made the "compliance and energy saving of clean air conditioning" its key research direction. It found the defects and deficiencies in ventilation systems' operation and expected to develop a patented product "digital high-efficiency air supply unit".
After in-depth communication and market analysis, the two parties reached a strategic cooperation and successfully developed digital high-efficiency air supply units. The digital high-efficiency air supply unit is applicable in high-risk products with rigorous cleanliness requirements in cell therapy such as vaccines, biological products, sterile preparations, sterile APIs, blood products, CAR-T, etc.
It can realise real-time air volume monitoring and rapid response adjustment, realize online air volume balance and pressure difference control, lower compliance risks, and solve the intractable pressure difference in the industry. It can achieve precise air supply, reduce energy waste every day, shorten the debugging time, and achieve preventive maintenance by trend analysis, which truly realizes energy-saving and intelligence.
Michel Moulin, Managing Director of Camfil Group China, said: "We are honoured to enter into a strategic partnership with Sinopharm GEPTECK. Camfil has a long track record of successful cases in the life sciences, especially in the pharmaceutical sector. And our products are widely used by world-renowned pharmaceutical companies."
"We have made an all-out effort to facilitate the production of vaccine manufacturers to protect people's health in the fight against COVID-19," added Moulin. "We hope to leverage the advantages of both parties and jointly promote the technological development of high-efficiency air units in the pharmaceutical industry, and help pharmaceutical companies to operate more safely and efficiently while saving more energy."
Wang Yunbao, General Manager of Sinopharm GEPTECK, pointed out: "The patented digital high-efficiency air supply unit independently developed by Sinopharm CEPTECK for five years has overthrown its traditional counterparts, and realised the digital control of air volume and cleanliness through air outlet with the advanced digital control system."
The strategic partnership between Sinopharm GEPTECK and Camfil Group China will bring opportunities to both parties and give full play to their joint technological advantages, product advantages, market advantages, and platform advantages. Together, they will adhere to win-win cooperation, leverage their respective advantages, and carry out all-around cooperation, making a greater contribution to boosting the progress of the biomedical industry.
With the introduction of the "Fourteenth Five-Year Plan for Biomedical Industry' and relevant supportive policies, China's biomedical industry will usher in a "golden decade". In recent years, the state has stepped up support for biotechnology innovation and the development of the biological industry, which has kept the swift growing momentum of China's biopharmaceutical industry; as such, it will see an increasingly bigger pharmaceutical market in the future.
In addition, the COVID-19 outbreak has driven the demand for vaccines and other products, which will further scale up the market for China's biopharmaceutical industry.